https://www.iqvia.com/-/media/iqvia/pdfs/nemea/uk/disruption...Oh, I take it back now, I have found a reliable reference:
• Disruptive drugs and technologies. The number of novel biologic molecules approved by the EMA and
FDA has surged in the past three years. In 2016 50% of FDA new chemical entity approvals were for
biologics. This period of high biologic innovation output will bring drugs that will compete with and expand
the current biologic market. New technologies also have the potential to be game changing, both in
efficacy and technological platform
• Biologic asset revaluation. The biologic